{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:11Z","timestamp":1791375311358,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","award":["CSL Behring"],"award-info":[{"award-number":["CSL Behring"]}],"id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-transfusion-dependent beta-thalassemia (\u03b2-NTDT) is characterized by ineffective erythropoiesis, increased intestinal iron absorption, and iron overload. The ferroportin inhibitor, vamifeport, has been shown to improve erythropoiesis via decreases in serum iron and transferrin saturation levels in preclinical models and healthy volunteer studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this 12-week, double-blind, randomized, placebo-controlled, phase 2a study was to assess the safety and tolerability of vamifeport versus placebo in adults with \u03b2-NTDT (primary endpoint). Iron-related pharmacodynamic effects (preliminary efficacy) were also assessed as a secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized, adult patients weighing 40\u201359\u00a0kg and 60\u2013100\u00a0kg received vamifeport 60\u00a0mg and 120\u00a0mg (once [QD] or twice [BID] daily), respectively, for 12 weeks. Non-transfusion-dependent thalassemia was defined as transfusion requirements\u2009&lt;\u20095 units of red blood cells during the 24 weeks before randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-five patients were included (vamifeport QD\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099, BID\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912; placebo\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094); 64% were male and 56% weighed\u2009&lt;\u200960\u00a0kg. Baseline serum iron and transferrin saturation levels were similar across treatment groups. All treatment-emergent adverse events were mild\/moderate, and rates were similar across groups (vamifeport QD 67%, BID 58%; placebo 75%). There were no deaths or serious treatment-emergent adverse events and no clinically relevant changes in safety parameters. Serum iron and transferrin saturation levels decreased by 2\u00a0h after the first vamifeport dose (mean [standard deviation] decreased QD \u2212\u200912.2 [6.5], BID \u2212\u200914.5 [12.1] \u00b5mol\/L and QD \u2212\u200933.6 [18.9], BID \u2212\u200937.2 [27.6] %, respectively) and remained below baseline levels at each subsequent visit. There were no clinically meaningful changes in the placebo group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this 12-week study, vamifeport had a favorable safety\/tolerability profile, with no changes in hemoglobin levels\u2009\u2265\u20091.0\u00a0g\/dL, and promising pharmacodynamic effects versus placebo in adults with \u03b2-NTDT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, NCT04364269. Registered 01 April 2020; Prospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04364269?term=NCT04364269&amp;rank=1\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT04364269?term=NCT04364269&amp;rank=1<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04119-y","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:11:46Z","timestamp":1764076306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent \u03b2-thalassemia: results from a randomized phase 2a study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-0655","authenticated-orcid":false,"given":"Antonis","family":"Kattamis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Hermosilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szecs\u00f6dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"4119_CR1","doi-asserted-by":"publisher","unstructured":"Taher AT, Weatherall DJ, Cappellini MD, Thalassaemia L. 391. 2018 155\u201367 https:\/\/doi.org\/10.1016\/s0140-6736(17)31822-6.","DOI":"10.1016\/s0140-6736(17)31822-6"},{"key":"4119_CR2","doi-asserted-by":"publisher","first-page":"e27522","DOI":"10.1097\/md.0000000000027522","volume":"100","author":"TH Jaing","year":"2021","unstructured":"Jaing TH, Chang TY, Chen SH, Lin CW, Wen YC, Chiu CC. Molecular genetics of \u03b2-thalassemia: a narrative review. Med (Baltim). 2021;100:e27522. https:\/\/doi.org\/10.1097\/md.0000000000027522.","journal-title":"Med (Baltim)"},{"key":"4119_CR3","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.12688\/f1000research.12688.1","volume":"6","author":"E Fibach","year":"2017","unstructured":"Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia - an update. F1000Res. 2017;6:2156. https:\/\/doi.org\/10.12688\/f1000research.12688.1.","journal-title":"F1000Res"},{"issue":"1","key":"4119_CR4","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2019-129309","volume":"134","author":"R Taranath","year":"2019","unstructured":"Taranath R, Bourne G, Zhao L, Frederick B, King C, Liu D. Regulation of iron homeostasis by PTG-300 improves disease parameters in mouse models for beta thalassemia and hereditary hemochromatosis. Blood. 2019;134(1):3540. https:\/\/doi.org\/10.1182\/blood-2019-129309.","journal-title":"Blood"},{"key":"4119_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/17474086.2021.1935854","volume":"14","author":"J Porter","year":"2021","unstructured":"Porter J, Taher A, Viprakasit V, Kattamis A, Coates TD, Garbowski M, D\u00fcrrenberger F, Manolova V, Richard F, Cappellini MD. Oral Ferroportin inhibitor Vamifeport for improving iron homeostasis and erythropoiesis in \u03b2-thalassemia: current evidence and future clinical development. Expert Rev Hematol. 2021;14:633\u201344. https:\/\/doi.org\/10.1080\/17474086.2021.1935854.","journal-title":"Expert Rev Hematol"},{"key":"4119_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","volume":"133","author":"S Rivella","year":"2019","unstructured":"Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in \u03b2-thalassemia. Blood. 2019;133:51\u20138. https:\/\/doi.org\/10.1182\/blood-2018-07-815928.","journal-title":"Blood"},{"key":"4119_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/jci129382","volume":"130","author":"V Manolova","year":"2019","unstructured":"Manolova V, Nyffenegger N, Flace A, Altermatt P, Varol A, Doucerain C, Sundstrom H, D\u00fcrrenberger F. Oral Ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of \u03b2-thalassemia. J Clin Invest. 2019;130:491\u2013506. https:\/\/doi.org\/10.1172\/jci129382.","journal-title":"J Clin Invest"},{"key":"4119_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/ijms22020873","volume":"22","author":"N Nyffenegger","year":"2021","unstructured":"Nyffenegger N, Flace A, Doucerain C, D\u00fcrrenberger F, Manolova V. The oral Ferroportin inhibitor VIT-2763 improves erythropoiesis without interfering with iron chelation therapy in a mouse model of \u03b2-thalassemia. Int J Mol Sci. 2021;22:873. https:\/\/doi.org\/10.3390\/ijms22020873.","journal-title":"Int J Mol Sci"},{"key":"4119_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.25670","volume":"95","author":"F Richard","year":"2020","unstructured":"Richard F, van Lier JJ, Roubert B, Haboubi T, G\u00f6hring UM, D\u00fcrrenberger F. Oral Ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers. Am J Hematol. 2020;95:68\u201377. https:\/\/doi.org\/10.1002\/ajh.25670.","journal-title":"Am J Hematol"},{"key":"4119_CR10","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects, https:\/\/www.wma.net\/wp-content\/uploads\/2016\/11\/DoH-Oct2013-JAMA.pdf. Last Accessed, 11 November 2024."},{"key":"4119_CR11","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Last Accessed, 11 November 2024."},{"key":"4119_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trsl.2016.05.005","volume":"177","author":"MW Garbowski","year":"2016","unstructured":"Garbowski MW, Ma Y, Fucharoen S, Srichairatanakool S, Hider R, Porter JB. Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay. Transl Res. 2016;177:19\u2013e30. https:\/\/doi.org\/10.1016\/j.trsl.2016.05.005.","journal-title":"Transl Res"},{"key":"4119_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ajh.21075","volume":"82","author":"GJ Anderson","year":"2007","unstructured":"Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol. 2007;82:1128\u201331. https:\/\/doi.org\/10.1002\/ajh.21075.","journal-title":"Am J Hematol"},{"key":"4119_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.21317","volume":"84","author":"A Piga","year":"2009","unstructured":"Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84:29\u201333. https:\/\/doi.org\/10.1002\/ajh.21317.","journal-title":"Am J Hematol"},{"key":"4119_CR15","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1172\/JCI123191","volume":"129","author":"S Crippa","year":"2019","unstructured":"Crippa S, Rossella V, Aprile A, Silvestri L, Rivis S, Scaramuzza S, Pirroni S, Avanzini MA, Basso-Ricci L, Hernandez RJ, Zecca M, Marktel S, Ciceri F, Aiuti A, Ferrari G, Bernardo ME. Bone marrow stromal cells from \u03b2-thalassemia patients have impaired hematopoietic supportive capacity. J Clin Invest. 2019;129:1566\u201380. https:\/\/doi.org\/10.1172\/JCI123191.","journal-title":"J Clin Invest"},{"key":"4119_CR16","doi-asserted-by":"publisher","first-page":"1403458","DOI":"10.3389\/fimmu.2024.1403458","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Yao X, Zhang J, Yang J, Ni J, Wang Y. Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives. Front Immunol. 2024;15:1403458. https:\/\/doi.org\/10.3389\/fimmu.2024.1403458.","journal-title":"Front Immunol"},{"key":"4119_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2141.1980.tb01202.x","volume":"44","author":"DM Walford","year":"1980","unstructured":"Walford DM, Deacon R. Globin chain biosynthesis in iron deficiency. Brit J Haematol. 1980;44:201\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.1980.tb01202.x.","journal-title":"Brit J Haematol"},{"key":"4119_CR18","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1172\/JCI24141","volume":"115","author":"A-P Han","year":"2005","unstructured":"Han A-P, Fleming MD, Chen J-J. Heme-regulated eIF2\u03b1 kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and \u03b2-thalassemia. J Clin Invest. 2005;115:1562\u201370. https:\/\/doi.org\/10.1172\/JCI24141.","journal-title":"J Clin Invest"},{"key":"4119_CR19","doi-asserted-by":"publisher","first-page":"e130111","DOI":"10.1172\/jci.insight.130111","volume":"4","author":"A Matte","year":"2019","unstructured":"Matte A, Federti E, Winter M, Koerner A, Harmeier A, Mazer N, Tomka T, Di Paolo ML, De Falco L, Andolfo I, Beneduce E, Iolascon A, Macias-Garcia A, Chen JJ, Janin A, Lebouef C, Turrini F, Brugnara C. De Franceschi, Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of \u03b2-thalassemia. JCI Insight. 2019;4:e130111. https:\/\/doi.org\/10.1172\/jci.insight.130111.","journal-title":"JCI Insight"},{"key":"4119_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bjh.17479","volume":"194","author":"AT Taher","year":"2021","unstructured":"Taher AT, Viprakasit V, Cappellini MD, Kraus D, Cech P, Volz D, Winter E, Nave S, Dukart J, Khwaja O, Koerner A, Hermosilla R, Brugnara C. Haematological effects of oral administration of bitopertin, a Glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia. Br J Haematol. 2021;194:474\u20137. https:\/\/doi.org\/10.1111\/bjh.17479.","journal-title":"Br J Haematol"},{"key":"4119_CR21","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.3390\/ijms22137229","volume":"22","author":"F Longo","year":"2021","unstructured":"Longo F, Piolatto A, Ferrero GB, Piga A. Ineffective erythropoiesis in \u03b2-thalassaemia: key steps and therapeutic options by drugs. Int J Mol Sci. 2021;22:7229. https:\/\/doi.org\/10.3390\/ijms22137229.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4119_CR22","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2018-99-110885","volume":"132","author":"J Porter","year":"2018","unstructured":"Porter J, Kowdley K, Taher A, Vacirca J, Shen Z, Chen S, Chawla L, Tidmarsh G. Effect of LJPC-401 (synthetic human hepcidin) on iron parameters in healthy adults. Blood. 2018;132(1):2336. https:\/\/doi.org\/10.1182\/blood-2018-99-110885.","journal-title":"Blood"},{"key":"4119_CR23","unstructured":"ClinicalTrials.gov. A study with LJPC-401 for the treatment of myocardial iron overload in patients with transfusion-dependent beta thalassemia, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03381833. Last Accessed, 11 November 2024."},{"key":"4119_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/thalassrep12030017","volume":"12","author":"TY Au","year":"2022","unstructured":"Au TY, Benjamin S, Wi\u015bniewski OW. Is the role of Hepcidin and erythroferrone in the pathogenesis of beta thalassemia the key to developing novel treatment strategies? Thalass Rep. 2022;12:123\u201334. https:\/\/doi.org\/10.3390\/thalassrep12030017.","journal-title":"Thalass Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04119-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:11:49Z","timestamp":1764076309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04119-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4119"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04119-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki, the International Council for Harmonization guidelines for Good Clinical Practice, and all relevant local, federal, or country regulatory requirements. All participants provided written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AK reports consultancy\/advisory board membership for Agios, Bristol Myers Squibb, Chiesi, Crisp\/Vertex, Ionis, Novartis, Silence Therapeutics, and CSL Vifor; and research funding from Bristol Myers Squibb and Novartis. AT has acted as a consultant and received research funding from Agios, Bristol Myers Squibb, Celgene, Novartis Pharmaceuticals, Pharmacosmos, and CSL Vifor. VV reports research funding from the Research Excellent Development Program, Faculty of Medicine Siriraj Hospital, Mahidol University, Biorad, Celgene, GPO (Thailand), La Jolla, Novartis, Protagonist, Roche Diagnostics, Sebia, Silence Therapeutics, and CSL Vifor. CL has no conflicts of interest to declare. RH and PS are employees of CSL Vifor. FR was previously employed by CSL Vifor. He is currently employed by Heidelberg Pharma AG. MDC is an advisory board member for Celgene, CRISPR, Novartis, Novo Nordisk, Sanofi\/Genzyme, and CSL Vifor. JP has served on advisory boards for Agios, Bluebird Bio, Bristol Myers Squibb, Celgene, Protagonist, and Silence Therapeutics, and CSL Vifor.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"608"}}